Introduction
Human breast cancers are heterogeneous in several aspects, including histopathological features and gene expression profiles. These tumors arise from the breast epithelium as a result of genetic mutations and epigenetic changes. However, the breast epithelium is composed of cells at different stages of differentiationa small number of mammary stem cells and bipotential progenitor cells give rise to larger populations of more differentiated ductal (or luminal) epithelial cells and myoepithelial (basal) cells Stingl et al., 2006; Bai and Rohrschneider, 2010) . These differentiated progeny constitute the bulk of the mammary epithelium. Stem and progenitor cells have been suggested to be the cells of origin for leukemia and solid cancers, including those arising in the colon, prostate and brain (Visvader, 2011) . However, it has been controversial whether breast cancers arise from stem cells, progenitor cells or their differentiated progeny, or whether they may arise from different subsets of cells, in which case differences in the cell of origin could be at least partly responsible for the phenotypic heterogeneity of breast cancer (Li and Rosen, 2005; Lim et al., 2009; Molyneux et al., 2010) .
Mouse models can be very powerful in addressing these issues. Many mouse models have been made to target oncogenic lesions primarily to the more differentiated luminal mammary cells through the use of the promoter of the gene encoding WAP (whey acidic protein) or the mouse mammary tumor virus (MMTV) long terminal repeat (LTR), both of which are known to be more highly expressed in the bulk, more differentiated mammary epithelial cells (Vargo-Gogola and Rosen, 2007) . These studies have discovered that differentiated luminal cells may be the origin of ErbB2 þ breast cancer (Li et al., 2003; Andrechek et al., 2004; Henry et al., 2004; Jeselsohn et al., 2010) . However, it has not been possible to introduce genetic alterations selectively into the precursor populations of mammary cells in vivo to investigate their tumor susceptibility or their influence on the phenotypes of the resulting tumors. This was largely a technical issue: To manipulate cancer genes for in vivo tumor studies, a single gene promoter typically has to be used to direct the transgenic expression of an oncogene (or Cre for deletion of a tumor-suppressor gene). s-SHIP, axin2 and low-density lipoprotein receptor-related protein 5 (LRP5) have recently been reported to enrich for mammary stem cells (Badders et al., 2009; Bai and Rohrschneider, 2010; Zeng and Nusse, 2010) , whereas CD24 and Sca1 could classify mammary cells into different differentiation subsets based on levels of their expression (Welm et al., 2002; Sleeman et al., 2006) ; but none could define mammary progenitor cells.
The keratin 6 (K6 or Krt6) gene family is composed of three members, namely K6a, K6b and K6hf (or Krt75) (Wojcik et al., 2001) . Only K6a is expressed in the mammary gland, and only in a very small fraction of mammary luminal epithelial cells based on co-staining with keratin 8 and estrogen receptor (Smith et al., 1990; Li et al., 2003; Grimm et al., 2006) . K6a is found in more mammary cells when the ductal tree expands, such as at the onset of puberty or early pregnancy (Smith et al., 1990; Grimm et al., 2006) . This distribution pattern is consistent with the distribution of mammary progenitors. Furthermore, K6a has been found by quantitative PCR to be more highly expressed in the population of mammary cells that are enriched for cells with colony-forming potential in collagen gel , but it has not been shown what percentage of cells in this population express K6a, and whether K6a þ cells in this population can actually form a colony or have other progenitor properties. Here, we report that K6a þ cells in the mammary gland are indeed bipotential progenitor cells and that they can be induced to form mammary tumors that resemble the normal-like breast cancer subtype in patients.
Results
Generation of K6a-tva BAC transgenic mice To conclusively determine whether K6a þ cells are progenitor cells, it was necessary to isolate live K6a þ cells away from the bulk of the mammary epithelium and test them in commonly used progenitor cell assays, such as colony-forming and transplantation assays. K6a is a cytoskeleton protein rather than a surface protein; hence, it was not amenable to antibody-mediated fluorescence-activated cell sorting (FACS) of live cells. To isolate live K6a þ cells, we placed tumor virus A (tva)-a gene encoding the cell-surface receptor for an avian leukosis virus, subgroup A (ALV/A) (Bates et al., 1993) -behind the K6a promoter in a BAC transgenic construct (Supplementary Figure 1) . Pronuclear injection of this transgenic construct into fertilized eggs from FVB/N mice resulted in one founder line. In this line, TVA was detected in a small fraction of cells among the luminal layer of ducts and body cells of terminal end buds at 5 weeks of age: Among 29 mammary sections made from 29 transgenic mice, 7 were found to have a few positive cells in the luminal layer and among body cells (Figure 1a) . By flow-cytometry analysis, TVA þ cells were estimated to be present at a frequency of B400 per million mammary cells (Figures 1c and d) . These TVA þ mammary cells, like K6a þ cells, could be increased significantly by daily subcutaneous administration of estrogen and progesterone for 5 days, which stimulated ductal expansion; TVA þ cells could now be detected in every section ( Figure 1b ) and at six-to sevenfold greater frequency based on flow cytometry (Supplementary Figure 2 ). To confirm that TVA þ cells also express K6a, mammary sections from three of the estrogen/progesterone-treated 7-week-old K6a-tva mice were co-stained for TVA and pan-K6. All TVA þ cells were also stained for K6, confirming that tva expression is restricted to K6 þ cells, although only a subset (26±4%) of K6 þ cells was also positive for TVA (Figures 1e and f) . To further verify that the tva expression is restricted to the K6 þ cell population, we also stained sections of hyperplastic mammary glands from three 12-week-old K6a-tva/MMTV-Wnt1 bi-transgenic mice and sections of mammary tumors arising in this line of mice. Again, all TVA þ cells were also positive for K6, whereas 65±9% and 22±5% of K6 þ cells in these hyperplastic and cancerous mammary tissues, respectively, also stained for TVA (Supplementary Figures 3a and b) . In addition, we detected TVA in K6 þ populations of cells in a number of non-mammary tissues, including the skin (in the outer root sheath of the hair follicle), esophagus, trachea, papilla of the dorsal tongue and sole of the foot (Supplementary Figure 3c) , but not aberrantly in K6-negative tissues, including the connective muscle and nervous tissues (data not shown). As expected of K6, after topical treatment with phorbol ester 12-O-tetradecanoylphorbol-13 acetate, TVA was also induced in the epidermis in the skin, ear and foot, and it continued to be restricted to the K6 þ cell population (Supplementary Figure 3c and data not shown). Collectively, these data demonstrate that tva expression is restricted to the K6 þ subset of cells in this K6a-tva transgenic line. The lack of detectable TVA in some of the K6 þ cells in these tissues may be because of lower TVA detection sensitivity relative to that for K6, shorter TVA half-life or the loss of transcriptional regulatory elements in this BAC construct.
The expression of tva was also expected to cause these K6a þ cells to be susceptible to infection by ALV/A (Du et al., 2006) , a useful feature for virus-mediated lineage tracing and introduction of oncogenes for tumor induction. To confirm that the TVA produced in K6a-tva mice was capable of mediating infection by RCAS (a modified version of ALV/A), we injected RCAS-GFP (green fluorescent protein) intraductally into mammary glands in nine K6a-tva mice at 5 weeks of age (10 7 IU per gland). Two and a half days after injection, we collected mammary glands from these infected mice, prepared single-cell suspensions and quantified the number of GFP þ cells by flow cytometry (Figure 1g ). In all, 13 ± 4 GFP þ cells were detected per million mammary cells (Figure 1h ). This infected cell number is much lower than the 0.3% achieved in MMTV-tva mice (Du et al., 2006) . This difference was expected, as the pool of RCAS-susceptible cells in K6a-tva mice is much smaller than that in MMTV-tva mice. As anticipated, no positive signal was detected in non-transgenic mice (Figures 1g and h ). . Next, we stained single-cell suspensions from 5-week-old K6a-tva and MMTV-tva mice for TVA, CD24 and CD49f; the Lin staining was omitted so as to accommodate the FACS channel for TVA detection ( Figure 2b ). As shown in Figure K6a-tva mice were enriched in the Ma-CFC group (27.5 ± 16.8%), but were rarely found in the MRU population. This result suggests that K6a-expressing cells are enriched for progenitor cells but not for stem cells, consistent with a previous report of quantitative PCR analyses of different subsets of mammary cells for K6a mRNA . In accordance, 50% of these TVA þ cells were also positive for CD61 ( Supplementary  Figure 4) , a marker that has been reported to be enriched in mammary progenitor cells (Asselin-Labat et al., 2007; Vaillant et al., 2008) . Among TVA þ from MMTV-tva mice, 6.9 ± 3.8% and 2.0 ± 1.5% were in Ma-CFC and MRU sub-populations, respectively (Figure 2c ), and 32±18% were positive for CD61 (Supplementary Figure  4) , confirming that the MMTV LTR may also be active in some progenitor and stem cells.
The mammosphere-forming assay is a surrogate assay for breast stem cells (Dontu et al., 2003) . In this assay, if undifferentiated mammary cells express tva and are susceptible to infection by RCAS-GFP, they would be expected to develop into green mammospheres. We first confirmed that RCAS-GFP infection of mammary cells prepared from 5-week-old MMTV-tva mice resulted in green mammospheres frequently (61±7%) (mean±s.d.) (Supplementary Figure 5a) , suggesting that the majority of mammosphere-initiating cells in MMTV-tva mice were TVA þ and susceptible to infection by RCAS. In a parallel experiment, we found that cells from 5-week-old K6-tva mice failed to form green mammospheres (0/ 1152 mammospheres in 18 culturing wells), but generated 3 ± 3 much smaller spheres of green cells per culture well (Supplementary Figure 5a) . These observations suggest that TVA þ cells from K6a-tva mice are susceptible to ex vivo infection in the mammosphere assay and have limited progenitor potential, but lack the self-renewal and robust proliferation properties defined in this assay.
To further evaluate the progenitor property of TVA þ cells in K6a-tva mice, mammary cells from 5-week-old K6a-tva and MMTV-tva mice, as well as wild-type mice were seeded in a colony-forming assay in the presence of RCAS-GFP for the first 16 h to infect the original TVA þ cells. Overall, 48% of the resulting colonies in the MMTV-tva group were green (Supplementary Figure  5b) . Although TVA þ cells in the K6-tva group were 500-fold less than those in the MMTV-tva group, the frequency of green colonies in the K6-tva group reached 4%. Therefore, the relative colony-forming efficiency of TVA þ cells in the K6a-tva group seems much higher than that in MMTV-tva mice (although we could not be certain that TVA þ cells in these two groups had the same plating efficiency). Furthermore, we found that these green colonies from K6-tva mice contained keratin 8 (K8) þ cells and cells positive for a-smooth muscle actin (aSMA) (Supplementary Figures 5c and d Figure 6 ). Approximately half of the ductal cells would have been positive for TVA if the outgrowths came from residual host ducts, based on our previous characterization of this MMTV-tva line (Du et al., 2006) . Single-cell suspensions were prepared from 9-week-old FVB mouse mammary glands and stained for Lin (CD45, Ter119, CD31 and CD140), CD24 and CD49f. Lin þ cells were gated out, and Ma-CFC (green circle) and MRU (black circle) populations were then identified as reported previously . This profile was used to draw the location of Ma-CFC and MRU in the rest of the study presented in this figure. (b, c) Single-cell suspensions from 5-week-old K6a-tva (n ¼ 6) and MMTV-tva mice (n ¼ 7) were stained for CD24, CD49f and TVA. Lin staining was omitted to accommodate the additional channel required for detection of TVA. Mouse model of normal-like breast cancer W Bu et al Our observation of very limited outgrowths from transplanted K6a-tva-expressing cells was in sharp contrast to much more extensive outgrowths (X40%) observed in fat pads transplanted with stem cellenriched MRU cells, but similar to the outgrowths (3 and 6%) from 2 of the 6 transplantations using 200 Ma-CFC cells (Figures 2d and e) . Nevertheless, these partial outgrowths were normal in histology (Figure 2f) , and contained both K8 þ epithelial cells and aSMA þ myoepithelial cells, as well as both estrogen receptor (ER)a þ and ERa À cells (Figure 2g ). Therefore, this small subset of K6a þ mammary cells exhibit restrictedbut frequently detectable-ductal outgrowth potential, suggesting that they are mammary bipotential progenitor cells, but not stem cells. Combined analysis of the data from our small transplantation experiments indicates violation of the single-hit Poisson model. For estimating the outgrowth-generating cell frequency, we incorporated all data into a generalized linear model and predicted the frequency at a dose of 200 cells (Figure 2d ). The frequency of outgrowth-generating cells was estimated to be 1 per 220 FACS-isolated K6a-tva-expressing cells (approximate 95% confidence interval (95% CI): 1/75 to 1/645), 1 per 1/512 Ma-CFC cells (approximate 95% CI: 1/123 to 1/2120) and 1 per 67 MRU cells (approximate 95% CI 1/17 to 1/261)-the estimated stem cell frequency in this MRU control is comparable with what has been reported . The estimated frequency of outgrowth-generating cells among TVA À cells was 1/13 619 (approximate 95% CI: 1/310 to 1/598 646). It is noteworthy that transplantation assays using FACS-isolated cells probably results in a severe underestimation of the absolute outgrowthgenerating potential among K6a-tva-expressing cells and other subsets, as FACS is known to damage cells and decrease their viability (Mollet et al., 2008) .
Induction of mammary tumors in K6a-tva transgenic mice
We have previously reported that RCAS can be used to introduce oncogenes into TVA þ cells for tumor induction (Du et al., 2006) . To test whether tva-expressing K6a þ cells can be induced to form unique tumors, we first injected RCAS virus expressing the gene encoding polyoma middle T antigen (PyMT) (RCAS-PyMT) into five 5-week-old K6a-tva mice (10 7 IU per gland, 3 glands per mouse). We chose this viral protein for its potent role in activating multiple oncogenic signaling pathways including those mediated by Src, the Shc adapter protein and phosphatidylinositol 3-kinase (Dilworth, 2002) , increasing the likelihood that tumor evolution will occur rapidly even with infection of small numbers of cells. One week after infection by RCAS-PyMT, a few foci of atypical ductal hyperplasia or ductal carcinoma in situlike lesions could be detected on hematoxylin and eosin-stained sections of infected glands from each of the infected mice (Supplementary Figure 7a) . These lesions contained heterogeneous cell types, including K8 þ , aSMA þ and K6 þ cells (Supplementary Figure  7b) . It is noteworthy that aSMA þ cells were not simply uninfected myoepithelial cells recruited into these lesions, as they were also positive for the HA tag in PyMT (Supplementary Figure 7c) . Such cellular heterogeneity in these early lesions is consistent with their origin in bipotential progenitors, although not every lesion may be clonally derived. As expected, early lesions could not be detected in K6a-tva transgenic mice that were not injected with RCAS-PyMT, in K6a-tva mice injected with RCAS-GFP ( Supplementary  Figure 7a) or in non-transgenic FVB mice injected with RCAS-PyMT.
The rapid formation of these pre-malignant lesions suggests that palpable tumors would also form quickly in this line of mice after infection with RCAS-PyMT. Indeed, all of additional 19 K6a-tva mice infected at 5 weeks of age (10 7 IUs per gland, 3 glands per mouse) developed palpable tumors by 8 weeks of age, with a median latency of only 14 days (Figure 3a) . This observation of rapid tumorigenesis suggests that infected K6 þ cells did not require additional genetic/ epigenetic events to become cancerous. In accordance, multiple proviruses were detected in all four tumors analyzed by Southern blotting ( Supplementary  Figure 8) , suggesting an oligoclonal origin. (It is noteworthy that no more than 13 cells were infected per gland; hence, smear on a Southern blot was not anticipated). However, we cannot exclude the possibility that some or all of these four tumors were monoclonal but they arose from single cells that were infected by multiple viruses.
Pulmonary metastases were found in only 1 of the 14 tumor-bearing mice that were examined at necropsy. A small percentage of metastases was also noted in tumorbearing MMTV-tva mice infected by RCAS-PyMT (10 4 IU per gland; this lower viral dosage was used to achieve a similar rate of infection as in K6a-tva mice). As the numbers of metastases were small in both groups, a statistical difference could not be established.
RCAS-PyMT-induced tumors are different in K6a-tva mice vs MMTV-tva mice in histopathology and epithelialto-mesenchymal transition RCAS-PyMT-induced tumors (n ¼ 10) in MMTV-tva mice were adenocarcinomas, usually with compact acini (Figures 3A-C) (Du et al., 2006) , but they also harbored focal areas of spindle-like cells without glandular structure (inset in Figure 3Ba ). These spindle-like areas lacked the epithelial/myoepithelial markers b-catenin, Ecadherin, K8 and K5, but produced the mesenchymal marker vimentin ( Figure 3C and Supplementary Figure  9) . In contrast, RCAS-PyMT-induced mammary tumors in K6a-tva mice (n ¼ 10) were typically papillary and cystic with ample spaces between the papillary fingers ( Figures 3B-b and d) , although they also harbored focal areas of more compact acini. Spindlelike cell lesions were absent in these tumors, and large areas of vimentin-positive cells were accordingly not detected ( Figure 3C ). Therefore, we conclude that tumor histopathology and epithelial-to-mesenchymal transition are modestly different between RCAS-PyMT-induced tumors in K6a-tva mice vs MMTV-tva mice. 
Mouse model of normal-like breast cancer W Bu et al
As the MMTV LTR seems to be active in a wide range of mammary cells (Figure 2) , the cell of origin of tumors arising in MMTV-tva mice is uncertain. Nevertheless, RCAS-PyMT-induced tumors in MMTV-tva mice harbored both epithelial and myoepithelial tumor cells (Du et al., 2006) , suggesting that they may have an origin in the immature subset of mammary cells. Using immunostaining for K8, K19, K5, K14 and aSMA, we found that both epithelial and myoepithelial cell types were also present in RCAS-PyMT-induced tumors in K6a-tva mice (Supplementary Figure 10) , although the myoepithelial content appeared to be lower than the epithelial component. These myoepithelial tumor cells were indeed progeny of infected K6a þ cells, as many (but not all) of the aSMA þ cells were also positive for the HA tag in PyMT (Supplementary Figure 10b) . As expected, patchy staining for K6 or, to a lesser degree, TVA was also detected in these tumors ( Supplementary  Figures 10c and d) . The presence of heterogeneous tumor cells is consistent with an origin in bipotential progenitor cells.
RCAS-PyMT-induced tumors in K6a-tva mice uniquely resemble the normal-like breast cancer subset in women Expression arrays are frequently used to define and compare subtypes of breast cancers. Therefore, we performed Affymetrix (Santa Clara, CA, USA) array analysis of five RCAS-PyMT-induced tumors each from K6a-tva mice and MMTV-tva mice, as well as five MMTV-PyMT transgene-induced mammary tumors, which are composed of luminal epithelial tumor cells (Rosner et al., 2002; Li et al., 2003) . On the basis of unsupervised hierarchical clustering of 1136 probe sets identified as different by ANOVAs (analyses of variance) (Po0.001), these three sets of tumors were segregated into two distinct clusters-one was composed of tumors induced by RCAS-PyMT in K6a-tva transgenic mice, whereas the other was composed of two sub-clusters, one for RCAS-PyMT-induced tumors in MMTV-tva transgenic mice and the other for tumors arising in MMTVPyMT transgenic mice (Figure 4a ). These results indicate that mammary tumors arising in RCAS-PyMT-infected K6a-tva mice are distinct from those arising in RCASPyMT-infected MMTV-tva mice or in MMTV-PyMT mice. Of particular interest, although basal cells were found in RCAS-PyMT-induced tumors in both tva lines but not in MMTV-PyMT transgene-induced tumors, RCAS-PyMT-induced tumors in MMTV-tva transgenic mice were, nevertheless, more similar to MMTV-PyMT transgene-induced tumors, possibly reflecting their closer similarity in the cell of origin-both cohorts of tumors must have arisen from cells in which the MMTV LTR is active. Herschkowitz et al. (2007) have reported expression profiles of 13 different mouse models of breast cancer and normal mammary glands from FVB and BALB/c mice. Therefore, we compared our expression data with the raw data from that report, by computing the correlation between each of our tumor profiles and each of the Herschkowitz mouse tumor profiles. As expected,
Negative correlation between profiles (P<0.01)
TgC3 ( None of the 13 previously characterized mouse models of human breast cancer resembles the normallike breast cancer subtype seen in patients (Herschkowitz et al., 2007) . The close similarity of the expression profiles of our K6a þ cell-derived tumors with that of normal mammary glands suggests that these K6a þ cellderived tumors may also resemble normal-like breast cancer in women. To test this possibility, we compared our expression arrays with the published database of expression arrays of human breast cancer samples from the study by Hoadley et al. (2007) , using only orthologous gene probes that were found in both array platforms. As anticipated, RCAS-PyMT-induced tumors in K6a-tva mice were tightly correlated with this subset of human breast cancers (Figure 4c ) (Pearson's Po1E-20, each K6a-tva tumor). In contrast, neither MMTV-PyMT transgene-induced mammary tumors nor RCAS-PyMT-induced tumors in MMTV-tva mice associated with normal-like breast cancers (Figure 4c ).
Collectively, these findings demonstrate that tumors arising from K6a þ bipotential progenitor cells are unique in that they recapitulate the normal-like breast cancer subtype in patients.
Discussion
Mammary stem and progenitor cells are ill-defined because of the lack of specific markers. Our results from mammosphere, colony-forming and transplantation assays demonstrate that K6a expression marks mammary bipotential progenitor cells but not stem cells. Previously, cells in the basal compartment have been found to have the potential to generate both basal and luminal lineages Stingl et al., 2006; Bai and Rohrschneider, 2010; Zeng and Nusse, 2010) . To our knowledge, this is the first observation of a subset of luminal epithelial cells and body cells that can give rise to both epithelial and basal cell lineages, and our study establishes K6 as the first single marker that can identify mammary bipotential progenitor cells. By expressing tva from the K6a promoter, we generated a mouse line in which tumorigenesis from these bipotential progenitor cells can be conveniently studied. We found that these cells are highly susceptible to transformation by PyMT and evolve into tumors that are distinct in histopathology, epithelial-to-mesenchymal transition and expression profiles from those arising in RCAS-PyMT-infected MMTV-tva mice. More importantly, unlike all 13 other mouse models of breast cancer the expression profiles of which have been compared with human breast cancers (Herschkowitz et al., 2007) , K6a þ cell-derived tumors resemble the normal-like breast cancer subtype in patients. This observation suggests that human normal-like breast cancers may also have an origin in bipotential progenitor cells. This first model of this subtype of human breast cancer provides a valuable preclinical tool for in vivo testing of therapeutic agents that may be especially effective in treating this subset of tumors. Although PyMT is a viral oncogene that is not found in human breast cancers, PyMT transforms breast cells through deregulating pathways (such as phosphatidylinositol 3-kinase-AKT signaling) that are commonly altered in human breast cancers. However, we do not yet know why these K6a þ cells uniquely give rise to this subtype of breast cancer, or whether introduction of a different oncogenic lesion into this subset of mammary cells would also lead to normal-like breast cancer.
The most likely explanation for the phenotypic differences between RCAS-PyMT-induced tumors in K6a-tva mice vs MMTV-tva mice is that in MMTV-tva mice, non-K6a þ cells were infected by RCAS-PyMT and evolved into tumors, and that the cell of origin had an impact on these cancer phenotypes. The cell of origin has been previously suggested to affect breast cancer phenotypes: For example, WAP expression is more restricted to the more differentiated subset of luminal cells than the MMTV LTR (Vargo-Gogola and Rosen, 2007) , and WAP-TAG (SV40T antigen) transgeneinduced mammary tumors differ from MMTV-TAG transgene-induced mammary tumors in gene expression profiles (Desai et al., 2002) . In addition, by using two different culture media to grow human breast cells from reduction mammoplasties, and then transforming them with a combination of oncogenes followed by transplantation into mice, Ince et al. (2007) found that the resulting tumors had different tumor phenotypes. However, the in vitro selection step used in that study adds uncertainty about the physiological and genetic state of cells before transformation. The observed phenotypic differences in these transgenic mouse model comparisons may also be caused by differences in the level of oncogene expression or the developmental stage when the transgene is expressed (the MMTV LTR becomes active at a much earlier developmental time than does the WAP promoter).
These concerns probably do not contribute to the phenotypic differences observed between tumors arising in RCAS-PyMT-infected K6a-tva mice vs MMTV-tva mice-the PyMT is expected to be expressed at similar levels in infected cells in these two lines of mice, because the RCAS LTR has been reported to be constitutively active (Fisher et al., 1999; Hughes, 2004) and unaffected by estrogen signaling (Toneff et al., 2010) , and we have confirmed a similar activity in infected cells in K6a-tva mice vs in MMTV-tva mice based on quantifying GFP intensity in RCAS-GFP-infected cells in these two lines of mice (734±61 vs 645±39). In addition, multifocal tumors developed with a short median latency of 14 days in both tva lines after RCAS-PyMT infection at 5 weeks of age, suggesting that no undefined secondary genetic alterations were involved in specifying the tumor phenotypes. Moreover, 1000-fold less viral particles were used to infect MMTV-tva mice than K6a-tva mice to achieve a similar low infection rate (no more than 10 infected cells per gland), minimizing a potential difference in tumor multiplicity. However, there might be a tumor modifier in the BAC transgene or in the genomic site where either transgene was inserted. Such a modifier might affect the potency of PyMT or the cellular response to PyMT-this is a caveat we cannot exclude when a single K6-tva founder transgenic line was used to compare with the single MMTV-tva line.
The identity of cells that evolved into tumors in RCAS-PyMT-infected MMTV-tva mice is yet to be defined, but cells of origin may be cells that have not yet committed to the luminal lineage, as basal cells were also found in RCAS-PyMT-induced tumors in MMTV-tva mice. They might be stem cells or a different subset of bipotential progenitor cells that do not express K6a. It is noteworthy that basal cells are usually infrequent in tumors arising in conventional MMTV transgenic models (Lindvall et al., 2007) . Although luminal committed progenitor cells or differentiated luminal cells may be the cells of origin in these conventional models, it is also possible that cells of origin are stem or bipotential progenitor cells-any basal progeny would stop expressing the initiating transgenic oncogene as MMTV LTR is known to be inactive in these cells (Du et al., 2006) ; thus, they would fail to expand.
In summary, we have demonstrated that K6a expression marks mammary bipotential progenitor cells, and that these K6a þ cells can be induced to form distinct normal-like tumors. We further conclude that the cell of origin affects breast cancer phenotypes. This new model offers a tool to study the evolution of normal-like breast cancer and to preclinically test potential therapeutic agents against this subtype, and provides an opportunity to test, in mammary bipotential progenitor cells specifically, oncogenic lesions that are directly implicated in human breast cancer.
Materials and methods
The MMTV-tva mouse line has been reported previously (Du et al., 2006) . MMTV-Wnt1 and MMTV-PyMT mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). The generation of the K6a-tva mouse line is described in Supplementary Information. All other materials and methods are detailed in Supplementary Information text.
